Cargando…

Differential gene expression and AKT targeting in triple negative breast cancer

Background: Metastatic triple negative breast cancer (mTNBC) is a heterogeneous disease with poor prognosis. Molecular evolution of TNBC through chemotherapy selection pressure is well recognized but poorly understood. PI3K/AKT/mTOR is one of the most commonly identified oncogenic-driver pathways in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Feng-Mao, Yost, Susan E., Wen, Wei, Frankel, Paul H., Schmolze, Daniel, Chu, Pei-Guo, Yuan, Yate-Ching, Liu, Zheng, Yim, John, Chen, Zhen, Yuan, Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6633890/ https://www.ncbi.nlm.nih.gov/pubmed/31320990 http://dx.doi.org/10.18632/oncotarget.27026

Ejemplares similares

CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer
por: Zhao, Zi-Ming, et al.
Publicado: (2019)

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023)

Multi-panel immunofluorescence analysis of tumor infiltrating lymphocytes in triple negative breast cancer: Evolution of tumor immune profiles and patient prognosis
por: He, Ting-Fang, et al.
Publicado: (2020)

Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer
por: Lee, Jin Sun, et al.
Publicado: (2022)

Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer
por: Lee, Jin Sun, et al.
Publicado: (2019)

Correction: Genomic mutation-driven metastatic breast cancer therapy: a single center experience
por: Yuan, Yuan, et al.
Publicado: (2017)

Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges
por: Lee, Jin Sun, et al.
Publicado: (2020)

Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer
por: Egelston, Colt A., et al.
Publicado: (2023)

Kinesin Family Member C1 (KIFC1/HSET) Underlies Aggressive Disease in Androgen Receptor-Low and Basal-Like Triple-Negative Breast Cancers
por: Jinna, Nikita, et al.
Publicado: (2023)

Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer
por: Yuan, Yuan, et al.
Publicado: (2019)

Genomic mutation-driven metastatic breast cancer therapy: a single center experience
por: Yuan, Yuan, et al.
Publicado: (2017)

Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer
por: Wen, Wei, et al.
Publicado: (2019)

Spatial distribution of B cells and lymphocyte clusters as a predictor of triple-negative breast cancer outcome
por: Wortman, Juliana C., et al.
Publicado: (2021)

Case Report: Significant Response to the Combination of Lenvatinib and Immune Checkpoint Inhibitor in a Patient With Heavily Pretreated Metastatic Triple Negative Breast Cancer
por: Lee, Jin Sun, et al.
Publicado: (2021)

Pathway activity profiling of growth factor receptor network and stemness pathways differentiates metaplastic breast cancer histological subtypes
por: McQuerry, Jasmine A., et al.
Publicado: (2019)

Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer
por: Egelston, Colt, et al.
Publicado: (2021)

LncRNAs as new biomarkers to differentiate triple negative breast cancer from non-triple negative breast cancer
por: Lv, Mingming, et al.
Publicado: (2016)

Mutation and immune profiling of metaplastic breast cancer: Correlation with survival
por: Afkhami, Michelle, et al.
Publicado: (2019)

Molecular subtypes of triple-negative breast cancer in women of different race and ethnicity
por: Ding, Yuan Chun, et al.
Publicado: (2019)

Role of AMPK and Akt in triple negative breast cancer lung colonization
por: Johnson, Jeremy, et al.
Publicado: (2021)

The development of activatable lytic peptides for targeting triple negative breast cancer
por: Zhao, Hui, et al.
Publicado: (2017)

Triple-Negative Breast Cancer
por: Chu, Quyen D., et al.
Publicado: (2012)

Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer
por: Li, Chia-Jung, et al.
Publicado: (2021)

Phase 2 prospective open label study of neoadjuvant nab‐paclitaxel, trastuzumab, and pertuzumab in patients with HER2‐positive primary breast cancer
por: Lavasani, Sayeh M., et al.
Publicado: (2022)

The Clinicopathological Features and Survival Outcomes of Different Histological Subtypes in Triple-negative Breast Cancer
por: Liao, Hong-Ye, et al.
Publicado: (2018)

ATRA-Induced Cellular Differentiation and CD38 Expression Inhibits Acquisition of BCR-ABL Mutations for CML Acquired Resistance
por: Wang, Zhiqiang, et al.
Publicado: (2014)

Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple negative breast and ovarian carcinomas
por: Menghi, Francesca, et al.
Publicado: (2022)

SERPINA1 is a direct estrogen receptor target gene and a predictor of survival in breast cancer patients
por: Chan, Hei Jason, et al.
Publicado: (2015)

Targeting Senescence as a Therapeutic Opportunity for Triple-Negative Breast Cancer
por: de Paula, Bruno, et al.
Publicado: (2023)

Berberine and Oligomeric Proanthocyanidins Exhibit Synergistic Efficacy Through Regulation of PI3K-Akt Signaling Pathway in Colorectal Cancer
por: Okuno, Keisuke, et al.
Publicado: (2022)

Thioguanine Induces Apoptosis in Triple-Negative Breast Cancer by Regulating PI3K–AKT Pathway
por: Zhang, Daoyu, et al.
Publicado: (2020)

Corrigendum: Berberine and Oligomeric Proanthocyanidins Exhibit Synergistic Efficacy Through Regulation of PI3K-Akt Signaling Pathway in Colorectal Cancer
por: Okuno, Keisuke, et al.
Publicado: (2022)

Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells
por: Swanner, Jessica, et al.
Publicado: (2015)

Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis
por: LIU, MIAO, et al.
Publicado: (2013)

Stemness signature and targeted therapeutic drugs identification for Triple Negative Breast Cancer
por: Gul, Samina, et al.
Publicado: (2023)

MicroRNA-454 may function as an oncogene via targeting AKT in triple negative breast cancer
por: Li, Qun, et al.
Publicado: (2017)

Detection of PIK3/AKT pathway in Moroccan population with triple negative breast cancer
por: Jouali, Farah, et al.
Publicado: (2018)

Sevoflurane Modulates AKT Isoforms in Triple Negative Breast Cancer Cells. An Experimental Study
por: Tiron, Crina E., et al.
Publicado: (2021)

Ceramide kinase mediates intrinsic resistance and inferior response to chemotherapy in triple‐negative breast cancer by upregulating Ras/ERK and PI3K/Akt pathways
por: Zhu, Shan, et al.
Publicado: (2021)

Accumulation of p62 is associated with poor prognosis in patients with triple-negative breast cancer
por: Luo, Rong-Zhen, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_elod1d38s7uaqab0an7t563ehu